In solid tumor investigations, AMPK blocked β-catenin trans-activation via activation-dependently inhibiting AKT-mediated phosphorylation of the β-catenin S552 site, which in turn reduced the transcript levels of CD274 (PD-L1) in cancer cells (70). This evidence concerns the gene CD274 and cancer.